Globin Solutions

Executive Summary

Globin Solutions, Inc. is a Boston-based pre-clinical biotechnology company dedicated to developing novel antidotal therapies for human poisonings, with an initial focus on carbon monoxide poisoning—the most common form of human poisoning. Leveraging expertise in globin chemistry and protein engineering, the company aims to create a rapidly acting antidote that can be administered in emergency settings. Founded in 2016, Globin Solutions operates in the competitive biologics space and has not yet disclosed total funding or valuation. As a private, pre-clinical entity, the company's progress is contingent upon advancing its lead candidate through IND-enabling studies and securing additional capital to support clinical development. The significant unmet medical need for effective carbon monoxide antidotes positions Globin Solutions as a potential key player in emergency medicine, though the early-stage nature of the company carries inherent development and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-Enabling Toxicology Studies70% success
• Q3 2026Series A Financing Round60% success